Erratum to Combined assessment of endothelial growth factor receptor dual color in situ hybridization and immunohistochemistry with downstream gene mutations in prediction of response to the Anti-EGFR therapy for patients with metastatic colorectal cancer[(2014), 45(5), 366] DOI: 10.1016/j.arcmed.2014.05.004;Combined Assessment of Endothelial Growth Factor Receptor Dual Color In Situ Hybridization and Immunohistochemistry with Downstream Gene Mutations in Prediction of Response to the Anti-EGFR Therapy for Patients with Metastatic Colorectal Cancer

Archives of Medical Research

Volumn 45, Issue 5, 2014, Pages 366-374

  Takahashi, Naoki ^a   Yamada, Yasuhide ^a   Taniguchi, Hirokazu ^a   Honma, Yoshitaka ^a   Iwasa, Satoru ^a   Kato, Ken ^a   Hamaguchi, Tetsuya ^a   Shimada, Yasuhiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

BRAF; Colon cancer; DISH; EGFR therapy; KRAS; NRAS; PIK3CA

Indexed keywords

B RAF KINASE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; FORMALDEHYDE; IRINOTECAN; K RAS PROTEIN; N RAS PROTEIN; PANITUMUMAB; PARAFFIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER THERAPY; CANCER TISSUE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; DISEASE ASSOCIATION; DISEASE CONTROL; DRUG EFFICACY; DUAL COLOR IN SITU HYBRIDIZATION; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MONOTHERAPY; ONCOGENE N RAS; OVERALL SURVIVAL; PREDICTION; PROGRESSION FREE SURVIVAL; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; WILD TYPE;

BRAF; COLON CANCER; DISH; EGFR THERAPY; KRAS; NRAS; PIK3CA;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GTP PHOSPHOHYDROLASES; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MEMBRANE PROTEINS; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84904613367     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2014.07.008     Document Type: Erratum

References (30)

1. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351:337-345.
2. Van Cutsem E., Peeters M., Siena S., et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007, 25:1658-1664.
3. Jonker D.J., O'Callaghan C.J., Karapetis C.S., et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007, 357:2040-2048.
4. Sobrero A.F., Maurel J., Fehrenbacher L., et al. EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:2311-2319.
5. Douillard J.Y., Siena S., Cassidy J., et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010, 28:4697-4705.
6. De Roock W., Piessevaux H., De Schutter J., et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008, 19:508-515.
7. Lièvre A., Bachet J.B., Boige V., et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008, 26:374-379.
8. Karapetis C.S., Khambata-Ford S., Jonker D.J., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008, 359:1757-1765.
9. Galizia G., Lieto E., Ferraraccio F., et al. Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery. Ann Surg Oncol 2006, 13:823-835.
10. Rego R.L., Foster N.R., Smyrk T.C., et al. Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status. Br J Cancer 2010, 102:165-172.
11. Saltz L.B., Meropol N.J., Loehrer P.J., et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004, 22:1201-1208.
12. Hebbar M., Wacrenier A., Desauw C., et al. Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer. Anticancer Drugs 2006, 17:855-857.
13. Chung K.Y., Shia J., Kemeny N.E., et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005, 23:1803-1810.
14. Moroni M., Veronese S., Benvenuti S., et al. Gene copy number for epidermal growth factor receptor EGFR and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005, 6:279-286.
15. Sartore-Bianchi A., Moroni M., Veronese S., et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 2007, 25:3238-3245.
16. Cappuzzo F., Finocchiaro G., Rossi E., et al. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol 2007, 194:717-723.
17. Personeni N., Fieuws S., Piessevaux H., et al. Cinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study. Clin Cancer Res 2008, 14:5869-5876.
18. Hoff K., Jørgensen J.T., Müller S., et al. Visualization of FISH probes by dual-color chromogenic in situ hybridization. Am J Clin Pathol 2010, 133:205-211.
19. De Roock W., Claes B., Bernasconi D., et al. Effects of KRAS, BRAF, NRAS and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010, 11:753-762.
20. Di Nicolantonio F., Martini M., Molinari F., et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008, 26:5705-5712.
21. Loupakis F., Ruzzo A., Cremolini C., et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009, 101:715-721.
22. Mao C., Yang Z.Y., Hu X.F., et al. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Ann Oncol 2012, 23:1518-1525.
23. Laurent-Puig P., Cayre A., Manceau G., et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009, 27:5924-5930.
24. Varella-Garcia M., Diebold J., Eberhard D.A., et al. EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer. J Clin Pathol 2009, 62:970-977.
25. Licitra L., Störkel S., Kerr K.M., et al. Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies. Eur J cancer 2013, 49:1161-1168.
26. Ålgars A., Lintunen M., Carpén O., et al. EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer. Br J Cancer 2011, 105:255-262.
27. Francoual M., Etienne-Grimaldi M.C., Formento J.L., et al. EGFR in colorectal cancer: more than a simple receptor. Ann Oncol 2006, 17:962-967.
28. Di Fiore F., Blanchard F., Charbonnier F., et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 2007, 96:1166-1169.
29. Mekenkamp L.J., Heesterbeek K.J., Koopman M., et al. Mucinous adenocarcinomas: poor prognosis in metastatic colorectal cancer. Eur J Cancer 2012, 484:501-509.
30. Liao X., Morikawa T., Lochhead P., et al. Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin Cancer Res 2012, 188:2257-2268.